Off-the-shelf immunotherapy for solid tumors

Discovery platform generating first-in-class candidates

We are pioneers in next-generation immuno oncology treatment

Thanks to our proteomics-driven precision & AI-powered prediction approach for a deeper undersanting of cancer complexities.

0 %

90% of patients currently undergoing treatment for solid tumors will experience treatment failure and relapse within the next 5 years.

This represents 10 million patients annually,
and is projected to increase by 70% by 2045.

Solid tumors remains the biggest challenge in cancer care

Cool Number

0 %

of patients will relapse

Cool Number

0 M

Annual mortality Worldwide

Tumor
antigens

Immune cell

Tumor cell

Multiple & evolving targets

Hiding from the immune system

CANCER IS
A MOVING TARGET

It constantly adapts under therapeutic pressure to express new tumor antigens invisble to the immune system.

Treatments fail to anticipate tumors’ evolution and relapse mechanisms
due to tumor plasticity : a key driver of cancer mortality.

Our Mission

Ensuring the immune system’s education,
to give back to patients the ability to target and destroy evolving tumor cells.

“STIMULATED GHOST CELL”INNOVATION

The successful equation to anticipate disease progression

OUR STIMULATED-(ghost)-TUMOR CELL (STC)  PLATFORM

MIMICS IN VITRO TUMORS RELAPSING CONDITIONS

CHARACTERIZED BY MULTI-OMICS ANALYSIS

GIVES BACK TO PATIENT THE ABILITY TO DESTROY TUMOR CELLS

REGARDLESS OF THEIR EVOLUTION

SAFELY ENSURES IMMUNE SYSTEM EDUCATION

+150 PRECISION CANCER-RELATED
TARGETS

Stimulated Ghost Cells presenting haptenated cancer-related antigens

RepresentING heterogeneity of the targeted indication

Strict & AI powered selection of starting material : Allogeneic tumor cell lines

  • Representative oncogenic drivers
  • Cold & Hot tumors
  • Resistances capacities

Safely ensurING immune system activation & EDUCATION

Haptenation and inactivation process leading to non-proliferative immunogenic ghost cells, to initiate a potent immune response against tumor cells.

MIMICKING PATIENT’S TUMORS RELAPSING CONDITIONS

Exposition to standards of care treatments :
+200 targets expressed, including cancer related antigens, linked to therapeutic pressure and resistances

Multi-omics characterization of targets
matching >5000 patient’s biopsies

COLORECTAL CANCER

REMAINS A HUGE UNMET NEED WORLDWIDE

PATIENTS PER YEARS

incidence

mortality

2.000.000

3rd most common cancer

1.000.000

2nd CAUSE OF CANCER MORTALITY

COLORECTAL CANCER

REMAINS A HUGE UNMET NEED WORLDWIDE

PATIENTS PER YEARS

incidence

mortality

2.000.000

3rd most common cancer

1.000.000

2nd CAUSE OF CANCER MORTALITY

our team

Our team is driven by passion and dedication, working in collaboration to bring innovative therapeutic solutions to patients.

THEY SUPPORT US

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens